HSPPC-90-CAlternative Names: HSPPC 90C
Latest Information Update: 06 Sep 2006
At a glance
- Originator Antigenics
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Jan 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 20 Apr 2000 Preclinical development for Cancer in USA (Unknown route)